建議您使用以下瀏覽器觀看本網站，
以獲得最佳瀏覽效果。
Company Profile
Panlabs Biologics—Leading in professional strain improvement and fermenting technology
Panlabs began as Panlabs Taiwan, Ltd, founded in 1971 by Mr. Hsi-Lin Chen, Dr. Merle Pindell and Dr. Joseph Lein in Taipei, Taiwan. In 2005, the core fermentation team, led by Mr. Benny Hu, branched off to form Panlabs Fermentation, which was later renamed Panlabs Biologics in June 2013.
Professional R&D, Customised Service
Panlabs is a contract research organization (CRO/CDRO) with over 50 years of experience in strain and enzyme improvement. Since its establishment, it has successfully completed over 300 projects and served hundreds of clients, specializing in developing high-yield strains for large-scale production.
Our services include:
- Strain selection and preservation
- Biomass transformation
- Anaerobic culture
- Fermentation process optimization
- CDMO fermentation production of APIs and their precursors/derivatives
Global Collaboration, Exceptional Partnerships
Panlabs serves customers worldwide, including in North America, Europe, and Asia, collaborating with internationally renowned pharmaceutical and biotech companies such as:
- North America: Eli Lilly, Merck & Co., Schering-Plough, Pfizer, Agennix, Warp Drive Bio, Zafgen, etc.
- Europe: GlaxoSmithKline (GSK), Sterling Drug, Sanofi (Hoechst), Fine Agrochemicals, Gist-Brocades, Cultor (Finnish Sugar), etc.
- Asia: Mitsubishi Chemical, Sanraku (Mercian), Daiichi Sankyo, Hindustan Antibiotics, Wockhardt (Merind), Zhejiang Hisun Pharmaceutical Co Ltd (Hisun), Chunghwa Chemical Synthesis & Biotech Co. Ltd., Yung Shin Pharmaceutical Industrial Co., Formosa Laboratories Inc., etc.
Innovative R&D & Future Expansion
In addition to our existing CRO, CDRO, and CDMO services, Panlabs is also actively advancing its own R&D projects. Based on market demand and with a commitment to safeguarding our customers' interests, we prioritize the development of high-value generic drugs and anticancer medications. This process begins with the improvement of strains and enzymes, leading to the establishment of a complete production process. Furthermore, to meet the demand for large-scale production and chemical synthesis, we have already established partnerships with high-quality domestic contract manufacturing partners to co-produce products that align with market needs.
Case Examples:
Ansamitocin P3 (Ansamitocin P-3; AP3; CAS: 66584-72-3):
In 2021, we successfully achieved kilogram-scale mass production and optimized the recovery and purification process to obtain high purity AP3. Additionally, we have also developed other successful products such as FR901379 (Micafungin intermediate; CAS: 144371-88-0), Staurosporine (CAS: 62996-74-1), and Calicheamicin γ1 (CAS: 108212-75-5). Currently, we are actively engaging with domestic and international Antibody-drug conjugate (ADC) development companies to explore more business opportunities and continue driving innovative R&D.
Valuable Resources
Panlabs has more than 20,000 strains of actinomycetes and fungi, which exhibit high diversity and uniqueness, offering a wealth of biological resources. Through systematic strain identification and strategic screening, we are able to discover high-value strains from our library for applications in the food, biotechnology, pharmaceutical, environmental, and materials industries, significantly shortening development timelines and enhancing production efficiency for our customers.
Looking to the Future, Continuing to Innovate
Panlabs will uphold the spirit of innovation that has driven us for over 50 years, continually refining our technology and enhancing our R&D capabilities. We strive to become the world's leading expert in strain and enzyme improvement, as well as a top biotechnology service company. We will provide comprehensive solutions to create maximum value for our customers and move toward an even brighter future.
Company advantage
50 years of expertise and R&D capabilities
- Random mutagenesis and rational screening strategies
- High-throughput mutant screening
- Integration of traditional mutagenesis with genetic engineering techniques
- Combination of strain and enzyme improvement with media optimization
Fermentation process optimization
- Increase production yield and reduce costs
- Reducing impurities and improving purity
- Development of stable strains for large-scale production
- Upstream and downstream process development with a one-stop service
Global microbial library and abundant biological resources
- Approximately 20,000 strains of fungi and actinomycetes
- Applied in discovery of bioactive substances
- Isolated from diverse geographical and environmental conditions, expanding application potential
- Not subject to the Nagoya Protocol, facilitating global collaboration
Customized service and demand orientation
- Feasibility study or integrated project development
- Fee-for-service or flexible payment options
- Technology transfer and application support
- Assistance for market access, accelerating commercialization
Company history
-
1971
Mr. Shi-Lin Chen, Dr. Merle Pindell, and Dr. Joseph Lein founded Panlabs Taiwan Ltd. in Taipei, Taiwan, focusing on pharmacological research, efficacy evaluation and drug development. -
1975
Established fermentation laboratories to engage in microbial strain improvement and fermentation technology research. -
1983
Established a molecular biotechnology laboratory in Seattle, USA, and named the company Panlabs International. -
2005
The core fermentation team was spun off to establish Panlabs Fermentation, focusing on strain improvement and fermentation technology. -
2013
Renamed the company Panlabs Biologics Inc., expanding its scope of biotechnology research and development. -
2014
Commenced the development of miniaturized fermentation systems, introduced an automatic liquid handling system, and significantly improved strain screening throughput. -
2015
Authorized the production strains and fermentation process of Micafungin (MCFG; S No: 235114-32-6) to a pharmaceutical company, showcasing the company’s ability to commercialize technology. -
2020
Entered the field of ADC (Antibody-dug cmplex) targeted therapeutics, providing payload intermediate supply to support clinical testing.
Licensed Staurosporine/Midostaurin production strain and provided fermentation, purification and semi-synthesis processes to foreign pharmaceutical companies. -
2021
Licensed the production strains and fermentation process of Penicillin to a foreign pharmaceutical company, expanding its antibiotic development and production capabilities.
